Fantasia Heidi Collins
Nurs Womens Health. 2014 Jun-Jul;18(3):237-41. doi: 10.1111/1751-486X.12125.
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause. This article will provide an overview of ospemifene and its indications, side effects and implications for nurses.
与绝经相关的雌激素水平下降会导致超过半数的绝经女性出现外阴阴道萎缩和一定程度的性交困难。2013年，美国食品药品监督管理局批准了奥培米芬，一种用于治疗绝经后性交困难的非激素类口服药物。本文将概述奥培米芬及其适应证、副作用以及对护士的意义。
